Pharmacopeia

CWP-0069

Corticosteroids — inhaled

Respiratory · Level 3

Core pharmacology

Class Group

Inhaled anti-inflammatory glucocorticoids; examples include budesonide, beclometasone and fluticasone.

Main Action

Suppress chronic airway inflammation and reduce asthma exacerbations; not a rapid rescue bronchodilator when used alone.

Mechanism of action

Intracellular glucocorticoid receptor activation changes gene transcription, reducing pro-inflammatory mediators and inflammatory-cell activity in airway mucosa.

Indications Uses

Foundational anti-inflammatory treatment of asthma; in COPD, use is selective (usually in combination inhalers according to exacerbation risk and phenotype), not universally indicated.

Absorption

Inhaled drug deposits in lung and oropharynx; pulmonary fraction may enter systemic circulation, while swallowed fraction undergoes drug-specific first-pass metabolism. Deposition and bioavailability vary with product and device.

Metabolism

For example, budesonide undergoes extensive hepatic first-pass metabolism (about 85–90%) to metabolites with much weaker glucocorticoid activity. Do not generalise this numerical PK to every inhaled steroid.

Adverse Effects Toxicity

Local oropharyngeal candidiasis, dysphonia and throat irritation; at higher cumulative systemic exposure, adrenal suppression, reduced bone density and other steroid effects. In COPD, pneumonia risk is clinically important.

Special Points

Rinse mouth/spit after inhalation and use appropriate inhaler technique. Some budesonide-formoterol products are used for anti-inflammatory reliever or MART strategies; ICS monotherapy is not a rapid rescue treatment. Follow National Asthma Council Australia guidelines and product-specific instructions.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.